ChimeriVax-JE Acambis

Current Opinion in Investigational Drugs

Volumn 4, Issue 8, 2003, Pages 1019-1023

  Jones, Taff ^a  

^a ID Biomedical Corporation of Quebec   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIVAX; INACTIVATED VIRUS VACCINE; JAPANESE ENCEPHALITIS VACCINE; PLACEBO; UNCLASSIFIED DRUG; YELLOW FEVER VACCINE;

ANTIBODY RESPONSE; CLINICAL TRIAL; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; EPIDEMIC ENCEPHALITIS; ERYTHEMA; HEADACHE; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION PAIN; NONHUMAN; PAIN; PREVALENCE; PROPHYLAXIS; REVIEW; SKIN MANIFESTATION; STRUCTURE ACTIVITY RELATION; SYSTEMIC DISEASE; VACCINATION; VIREMIA;

ANIMALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; ENCEPHALITIS VIRUS, JAPANESE; ENCEPHALITIS, JAPANESE; HUMANS; JAPANESE ENCEPHALITIS VACCINES; RANDOMIZED CONTROLLED TRIALS;

EID: 0141607915     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. 248636 Annual Report 1996 - OraVax Inc. OraVax Inc Annual Report 1996 February
2. 263068 OraVax acquires chimeric vaccine technology from St. Louis University; Patent filing covers a new class of single-dose viral vaccines. OraVax Inc Press Release 1997 September 16
3. 319689 Oravax Inc reports fourth-quarter and year end results - Peptide Therapeutics merger targeted to be completed early second quarter. OraVax Inc Press Release 1999 March 29
4. 325296 Recombinant, chimeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Monath TP, Soike K, Lenebook I, Zhang ZX, Arroyo J, Delagrave S, Myers G, Barrett ADT, Shope RE, Ratterree M Vaccine 1999 17 15-16 1869-1882 This paper describes the safety, immunogenicity and protection against challenge of Chimeri-Vax-JE in non-human primates. All vaccinees had neutralizing antibodies and five out of six were protected against encephalitis after challenge. No significant neurovirulence or histopathology was observed.
5. 382969 Peptide's interim second quarter financial results. Peptide Therapeutics Group Plc Press Release 2000 September 20
6. 392289 Completion for Baxter subscription, appointment of new director and change of name to Acambis plc. Peptide Therapeutics Group Plc Press Release 2000 December 05
7. 398727 ChimeriVax technology validated by successful clinical trial of JE vaccine. Acambis Plc Press Release 2001 February 12
8. 400669 Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: Dose-response effectiveness and extended safety testing in rhesus monkeys. Monath TP, Levenbook I, Soike K, Zhang ZX, Ratterree M, Draper K, Barrett AD, Nichols R, Weltzin R, Arroyo J, Guirakhoo F J Virol 2000 74 4 1742-1751 This paper describes the extended safety, immunogenicity and protection studies of the vaccine in non-human primates. No neurovirulence or histopathology was observed in the vaccinated monkeys, all of whom had neutralizing antibodies. All vaccines were protected against challenge.
9. 400670 Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Guirakhoo F, Zhang ZX, Chambers TJ, Delagrave S, Arroyo J, Barrett AD, Monath TP Virology 1999 257 2 363-372 This paper describes the genetic stability of ChimeriVax-JE, which was stable through 18 passages in tissue culture and six passages through mouse brain.
10. 417658 Acambis starts phase II trial of Japanese encephalitis vaccine. Acambis Plc Press Release 2001 August 01
11. 421925 ChimeriVax live attenuated vaccine against Japanese encephalitis: Proof-of-principle phase I/II clinical trial. Monath TP, Guirakhoo F, McCarthy K, Johnson C, Bedford P, Arroyo J ICAAC 2001 41 Abs G1580
12. 422720 Successful phase II challenge trial of ChimeriVax-JE vaccine. Acambis Plc Press Release 2001 September 20 This release announces encouraging results of the first phase II trial in which recipients of ChimeriVax-JE were challenged with inactivated virus. Compared with unvaccinated controls, vaccinees rapidly developed protective antibody levels indicating that ChimeriVax-JE had elicited the important memory responses required for long-lasting immunity.
13. 439889 ChimeriVax-JE vaccine successfully completes second phase II trial. Acambis Plc Press Release 2002 February 14 This press release describes positive results of the second phase II trial of ChimeriVax-JE. The vaccine was well tolerated at all doses tested, and 98% of the patients whose serum was available for analysis mounted a JE-neutralizing antibody response within 30 days after vaccination.
14. 452286 Clinical proof-of-principle for ChimeriVax: Recombinant live, attenuated vaccines against flavivirus infections. Monath TP, McCarthy K, Bedford P, Johnson CT, Nichols R, Yoksan S, Marchesani R, Knauber M, Wella H, Arroyo J, Guirakhoo F Vaccine 2002 20 7-8 1004-1018 This paper reports that ChimeriVax-JE was safe and well tolerated during phase I/II trials. All vaccinees developed neutralizing antibodies, and prior YF vaccination did not negatively impact on the immunogenicity of ChimeriVax-JE.
15. 454843 Preliminary results for the year ended 31 December 2001. Acambis Plc Press Release 2002 March 12
16. 464366 Acambis plc interim results for the six months ended 30 June 2002. Acambis Plc Press Release 2002 September 18
17. 471709 Acambis plc: Results for the third quarter ended 30 September 2002. Acambis Plc Press Release 2002 November 25
18. 481480 Acambis announces maiden profit of STG 9.6m. Acambis Plc Press Release 2003 March 11
19. 487568 Clinical trials of chimeric yellow fever/Japanese encephalitis (ChimeriVax-JE) vaccine. Monath TP, Blum P, Nicols R, McCarthy K, Bedford P, Guirakhoo F Am J Trop Med Hyg 2002 67 2 Suppl 340-341
20. 487570 Chimeric yellow fever 17D-Japanese encephalitis (ChimeriVax-JE) vaccine: Preclinical effectiveness and safety testing in Rhesus monkeys. Draper K, Soike K, Levenbook I, Guirakhoo F, Monath TP, Antiviral Res 2000 46 1 A84
21. 487571 Chimeric yellow fever-Japanese encephalitis vaccine is safe and effective in a monkey model. Monath TP, Guirakhoo F, Arroyo J, Zhang ZX, Delagrave S, Chambers TJ, Barrett AM, Shope RE, Soike KF Am J Trop Med Hyg 1998 59 3 Suppl 218
22. 488790 Acambis announces results for the first quarter ended 31 March 2003. Acambis Plc Press Release 2003 May 08
23. 497200 Japanese encephalitis vaccines: WHO position paper. Weekly Epidemiological Record 1998 73 337-344
24. 497462 Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): Phase II clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. Monath TP, Guirakhoo F, Nichols R, Yoksan S, Schrader R, Murphy C, Blum P, Woodward S, McCarthy K, Mathis D, Johnson C et al. J Infect Dis 2003 in press
25. 497887 Global Biotechnology: July Model Book - Biotechnology. Ende EJ, McGahren TJ, Cohen G, Vitiello R, Sambasivam H, Pollard M, Whittaker E, Welford P Merrill Lynch & Co 2003 July 02